Your browser doesn't support javascript.
loading
Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.
Shibayama, Takahiro; Hayashi, Akimasa; Toki, Masao; Kitahama, Keiichiro; Ho, Yu-Jui; Kato, Kenichiro; Yamada, Takahiro; Kawamoto, Sho; Kambayashi, Komei; Ochiai, Kazushige; Gondo, Koichi; Okano, Naohiro; Melchor, Jerry P; Iacobuzio-Donahue, Christine A; Sakamoto, Yoshihiro; Hisamatsu, Tadakazu; Shibahara, Junji.
Affiliation
  • Shibayama T; Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
  • Hayashi A; Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. hayashia@ks.kyorin-u.ac.jp.
  • Toki M; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Kitahama K; Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
  • Ho YJ; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kato K; Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
  • Yamada T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Kawamoto S; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Kambayashi K; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Ochiai K; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Gondo K; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Okano N; Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
  • Melchor JP; The David M. Rubenstein Center for Pancreatic Cancer Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Iacobuzio-Donahue CA; The David M. Rubenstein Center for Pancreatic Cancer Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sakamoto Y; Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.
  • Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Shibahara J; Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. jshiba@ks.kyorin-u.ac.jp.
Sci Rep ; 14(1): 15598, 2024 07 06.
Article de En | MEDLINE | ID: mdl-38971768
ABSTRACT
Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice remains to be identified. We aimed to evaluate the utility of immunohistochemistry (IHC) expression subtypes generated by unsupervised hierarchical clustering based on staining scores of four markers (CK5/6, p63, GATA6, HNF4a) applied to endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) materials. EUS-FNAB materials taken from 190 treatment-naïve advanced PDAC patients were analyzed, and three IHC patterns were established (Classical, Transitional, and Basal-like pattern). Basal-like pattern (high co-expression of CK5/6 and p63 with low expression of GATA6 and HNF4a) was significantly associated with squamous differentiation histology (p < 0.001) and demonstrated the worst overall survival among our cohort (p = 0.004). IHC expression subtype (Transitional, Basal vs Classical) was an independent poor prognosticator in multivariate analysis [HR 1.58 (95% CI 1.01-2.38), p = 0.047]. Furthermore, CK5/6 expression was an independent poor prognostic factor in histological glandular type PDAC [HR 2.82 (95% CI 1.31-6.08), p = 0.008]. Our results suggest that IHC expression patterns successfully predict molecular features indicative of the Basal-like subgroup in advanced PDAC. These results provide the basis for appropriate stratification for therapeutic selection and prognostic estimation of advanced PDAC in a simplified manner.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Immunohistochimie / Marqueurs biologiques tumoraux / Carcinome du canal pancréatique / Facteur de transcription GATA-6 / Facteur nucléaire hépatocytaire HNF-4 Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Sci Rep Année: 2024 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Immunohistochimie / Marqueurs biologiques tumoraux / Carcinome du canal pancréatique / Facteur de transcription GATA-6 / Facteur nucléaire hépatocytaire HNF-4 Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Sci Rep Année: 2024 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni